Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2010

View Archived Issues

SkyePharma receives FDA complete response letter regarding NDA for Flutiform

FDA sets PDUFA date for Genzyme's BLA for Lumizyme

Biogen and Swedish Orphan Biovitrum initiate dosing in B-LONG trial of rFIXFc in hemophilia B

Bayer to discontinue phase II trial of recombinant liposomal factor VIII

Clinical data shows nilotinib to be an effective front-line treatment for CML

Clinical data show safety and efficacy of dasatinib as initial therapy for CML

Shionogi discloses N-type calcium channel blockers as analgesics

Dana-Farber Cancer Institute claims novel antimalarials

Novel prostacyclin and carbaprostacyclin prodrugs in early development at Gilead

Amnestix describes novel kinase inhibitors for the treatment of cognitive disorders

Merck KGaA claims tyrosine kinase inhibitors for the treatment of cancer

Spectrum meets with FDA regarding Fusilev sNDA for colorectal cancer

Proangiogenic gene therapy reduces ventricular remodeling in diabetic rats

Roche presents OX-2 receptor antagonists for the treatment of sleep disorders

KV-11 shows preclinical potential as ocular antiangiogenic therapy

Affymax completes treatment in phase III trial of Hematide for anemia in CRF

Janssen-Cilag notifies EMEA of withdrawal of Comfyde MAA for partial-onset seizures

Merck & Co. claims novel PET imaging agents for the diagnosis of AD

Osiris completes enrollment in phase II trial of Prochymal in type 1 diabetes

Prolor Biotech reports preclinical results on interferon beta-CTP for multiple sclerosis

Anadys provides progress update on phase II study of ANA-598 in hepatitis C

EMEA recommends additional measures to manage risk for PML with Tysabri therapy

CHMP recommends suspension of marketing authorization for sibutramine

Transition Therapeutics reports results from phase II trial of TT-223 in type 2 diabetes

European Commission approves Bristol-Myers' Orencia in combination with MTX for pJIA

Dr. Reddy's and Aegis sign partnership agreement on Intravail drug delivery technology

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...